London, UK, July 21 10, 2022 (GLOBE NEWSWIRE) — Virax Biolabs Group Limited (“Virax” or the “&CloseCurlyDoubleQuote Company;) (Nasdaq: VRAX), an innovative biotechnology company focused on disease prevention, detection and diagnosis, today announced the closing of its initial public offering (IPO) and the company’s shares began trading today on the Nasdaq Capital Markets under the symbol “VRAX”.
The company’s IPO consisted of 1,350,000 common shares at a public offering price of $5.00 per share, for aggregate gross proceeds of $6.75 million, before deducting subscription discounts, commissions and other related expenses.
Boustead Securities, LLC acted as the underwriters’ representative for the firm commitment offering.
A registration statement relating to the securities sold pursuant to this offering was declared effective by the Securities and Exchange Commission on June 30, 2022. The offering of these securities has been made solely by means of a prospectus, forming part of the registration statement. A copy of the final prospectus relating to the offering may be obtained, when available, from Boustead Securities, LLC, by e-mail: [email protected] or by calling +1 (949) 502-4408 or by standard mail at Boustead Securities, LLC, Attn: Equity Capital Markets, 6 Venture, Suite 395, Irvine, CA 92618, USA. In addition, a copy of the final prospectus relating to the offering may be obtained through the SEC’s website at www.sec.gov.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company, and such securities will not be offered or sold in the United States absent registration or an applicable exemption from registration, and there will be no offer, solicitation or sale of any of the securities of the Company in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws securities of that state or jurisdiction.
About Virax BiolabsLimited group
Founded in 2013, Virax Biolabs Group Limited is an innovative biotechnology group focused on the detection and diagnosis of viral diseases, with a particular interest in the field of immunology.
Virax Biolabs Group Limited is currently developing proprietary T cell testing technology with the aim of providing an immunological profiling platform that assesses each individual’s immune risk profile against major global viral threats. The T cell test is particularly effective in the diagnosis and therapy of COVID-19 as well as other threats such as hepatitis B, malaria, herpes and human papillomavirus. For more information, please visit www.viraxbiolabs.com.
Safe Harbor Statement
This press release contains forward-looking statements. Additionally, from time to time, we or our representatives may make oral or written forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from information currently available to us. These forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our revenue and earnings growth; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “ believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. When evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technologies and changing market needs; and the competitive environment in which our business operates. These and other factors may cause that our actual results will differ materially from any forward-looking statements. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives may not s occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us. We are under no obligation to publicly update or revise any forward-looking statement, whether due to uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives may not occur. .
Virax Biolabs Group Limited
Cameron Shaw, COO
Telephone: +44 7954 488 982
Email: [email protected]
Contact with Investor Relations:
Skyline Business Communications Group, LLC
Lisa Gray, Senior Account Manager
One Rockefeller Plaza, 11th Floor
New York, NY 10020
Office: (646) 893-5835
E-mail: [email protected]